Abstract
The present disclosure is directed to dual specific antibodies, which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.
Full Text
What is claimed is:
The present disclosure is directed to dual specific antibodies, which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.
Timeline
Filed
04/20/2026Published
08/13/2026Granted
Not AvailableIPC Codes(3)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61P 35/00:Antineoplastic agents
G01N 33/575:for cancer